

ORIGINAL ARTICLE



The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: A cross-sectional multicenter study

Gizem Cengiz¹ | Kemal Nas² | Yaşar Keskin³ | Erkan Kılıç⁴ | Betül Sargin⁵ | Sevtap Acer Kasman⁶ | Hakan Alkan⁷ | Nilay Sahin⁸ | Nihan Cüzdan Balta⁹ | İlknur Albayrak Gezer¹⁰ | Dilek Keskin¹¹ | Cevriye Mülkoğlu¹² | Hatice Reşorlu¹³ | Şebnem Ataman¹⁴ | Ajda Bal¹⁵ | Merve Baykul² | Mehmet Tuncay Duruöz⁶ | Okan Küçükakkaş³ | Ozan Volkan Yurdakul³ | Meltem Alkan Melikoğlu¹⁶ | Fikriye Figen Ayhan¹⁷ | Hatice Bodur¹⁸ | Mustafa Çalış¹ | Erhan Çapkin¹⁹ | Gül Devrimsele²⁰ | Kevser Gök²¹ | Sami Hizmetli²² | Ayhan Kamanlı² | Hilal Ecesoy²³ | Öznur Kutluk²⁴ | Nesrin Şen²⁵ | Ömer Faruk Şendur⁵ | İbrahim Tekeoğlu² | Murat Toprak²⁶ | Sena Tolu²⁷ | Tiraje Tuncer²⁴

¹Division of Rheumatology, Department of Physical Medicine and Rehabilitation, School of Medicine, Erciyes University, Kayseri, Turkey

²Division of Rheumatology and Immunology, Department of Physical Medicine and Rehabilitation, School of Medicine, Sakarya University, Sakarya, Turkey

³Department of Physical Medicine and Rehabilitation, Bezmialem Vakıf University, Istanbul, Turkey

⁴Rheumatology Clinic, Kanuni Training and Research Hospital, Trabzon, Turkey

⁵Division of Rheumatology, Department of Physical Medicine and Rehabilitation, School of Medicine, Adnan Menderes University, Aydın, Turkey

⁶Division of Rheumatology, Department of Physical Medicine and Rehabilitation, School of Medicine, Marmara University, Istanbul, Turkey

⁷Department of Physical Medicine and Rehabilitation, School of Medicine, Pamukkale University, Denizli, Turkey

⁸Department of Physical Medicine and Rehabilitation, School of Medicine, Balıkesir University, Balıkesir, Turkey

⁹Division of Rheumatology, Department of Physical Medicine and Rehabilitation, School of Medicine, Hatay Mustafa Kemal University, Hatay, Turkey

¹⁰Department of Physical Medicine and Rehabilitation, School of Medicine, Selçuk University, Konya, Turkey

¹¹Department of Physical Medicine and Rehabilitation, School of Medicine, Kırıkkale University, Kırıkkale, Turkey

¹²Department of Physical Medicine and Rehabilitation, Ankara Training and Research Hospital, Ankara, Turkey

¹³Department of Physical Medicine and Rehabilitation, School of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey

¹⁴Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Ankara University School of Medicine, Ankara, Turkey

¹⁵Department of Physical Medicine and Rehabilitation, Dışkapı Yıldırım Beyazıt Training and Research Hospital, University of Health Sciences, Ankara, Turkey

¹⁶Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Atatürk University School of Medicine, Erzurum, Turkey

¹⁷Department of Physical Medicine and Rehabilitation, School of Medicine, Atılım University, Ankara, Turkey

¹⁸Department of Physical Medicine and Rehabilitation, School of Medicine, Yıldırım Beyazıt University, Ankara, Turkey

¹⁹Department of Physical Medicine and Rehabilitation, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

²⁰Department of Physical Medicine and Rehabilitation, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey

²¹Rheumatology Clinic, Ankara City Hospital, Ankara, Turkey

²²Division of Rheumatology, Department of Physical Medicine and Rehabilitation, School of Medicine, Cumhuriyet University, Sivas, Turkey

²³Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Meram School of Medicine, Necmettin Erbakan University, Konya, Turkey

²⁴Division of Rheumatology, Department of Physical Medicine and Rehabilitation, School of Medicine, Akdeniz University, Antalya, Turkey

²⁵Department of Rheumatology, Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey

²⁶Department of Physical Medicine and Rehabilitation, School of Medicine, Yüzüncü Yıl University, Van, Turkey

²⁷Department of Physical Medicine and Rehabilitation, School of Medicine, Medipol University, Istanbul, Turkey

© 2022 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

**Correspondence**

Gizem Cengiz, Division of Rheumatology,
Department of Physical Medicine and
Rehabilitation, Erciyes University, School
of Medicine, Kayseri, Turkey.
Email: gizemcng@outlook.com

Abstract

Aim: Nail involvement is common in psoriatic arthritis. This study assesses clinical characteristics, nail psoriasis prevalence, and impact of nail psoriasis on disease activity in patients with psoriatic arthritis (PsA).

Method: This cross-sectional multicenter study was conducted by the Turkish League Against Rheumatism using PsA patients recruited from 25 centers. Demographic and clinical characteristics of PsA patients, such as disease activity measures, quality of life, and nail involvement findings were assessed during routine follow-up examinations. Patients were divided into two groups according to the presence or absence of nail psoriasis and compared using the χ^2 test or Fisher exact test for categorical variables and the t-test or Mann-Whitney *U* test for continuous variables.

Results: In 1122 individuals with PsA, 645 (57.5%) displayed nail psoriasis. The most frequent features of fingernails were ridges (38%), followed by pitting (21%) and onycholysis (19%). More females were present in both groups (with and without nail psoriasis; 64% vs 67%, $P < 0.282$). Patients with nail psoriasis were older, indicated more pain and fatigue, experienced greater swelling, tender joint counts, and skin disease severity, and had a higher disease activity score compared with those without nail psoriasis (all $P < 0.05$).

Conclusion: We demonstrate an increased prevalence of nail psoriasis observed in patients with psoriatic arthritis. Patients with nail involvement experience increased disease activity, lower quality of life, and diminished mental and physical status compared with those without nail involvement.

KEYWORDS

clinical characteristics, disease activity, nail involvement, nail psoriasis, psoriatic arthritis, quality of life

1 | INTRODUCTION

Psoriatic arthritis (PsA) is a chronic, immune-mediated systemic disease that may present with arthritis, dactylitis, enthesitis, spondylitis, and skin and nail disease, as well as a variety of linked comorbidities, such as uveitis, osteoporosis, cardiovascular disease, and subclinical inflammatory bowel disease.^{1–3} Psoriasis is an inflammatory disease of the skin, present in 1%–3% of the worldwide population and is associated with cancer, diabetes, metabolic syndrome, and cardiovascular disease.^{2,4–6} PsA prevalence varies between 6% and 41% in patients with psoriasis.^{7–9} Nail involvement prevalence in patients with PsA ranges from 41% to 93%⁷ and from 15% to 50%,^{7,10} among patients with psoriasis. Nail psoriasis is seen alone in about 1%–5% of patients.¹¹ Changes to the nails, such as crumbling, pitting (shallow depressions), leukonychia (white discoloration), onychorrhexis (longitudinal nail ridges, splits, or fissures), or red spots in the lunula occur in matrix involvement,^{10,12} whereas onycholysis (disjunction between the nail bed and nail plate), splinter hemorrhages, subungual hyperkeratosis (thickening of the nail plate), and

oil-drop discoloration (salmon patches) occur in nail bed involvement.¹³ Pitting is not specific to psoriasis—it is observed in chronic eczema and alopecia areata—but 10 pits on a single nail or more than 50 pits on all nails are considered evidence of psoriasis.¹⁴ Oil-drop discoloration is a quite specific finding for nail psoriasis; however, indicators such as onycholysis, other discoloration, and subungual hyperkeratosis are sensitive but less specific.^{13,14}

The presence of psoriatic nail disease is accepted as evidence of the development of PsA.^{15,16} A microanatomical relation between nail involvement and specific disease features, such as dactylitis and enthesitis,¹⁷ has established that these are accepted hallmarks of PsA. Moreover, a link between erosive distal interphalangeal (DIP) joint involvement and nail disease features has been demonstrated in previous studies.^{18,19} In addition, an imaging study has shown that DIP joint involvement is secondary to nail involvement in PsA patients.²⁰ The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommendations emphasizes the recognition and management of each of the main manifestations of PsA (enthesitis, dactylitis, skin disease, nail disease, axial disease, and peripheral



arthritis) as well as the screening for and treatment of comorbidities.²¹ National and international guidelines for psoriasis management prioritize treatment selection.^{22,23} Currently, various local or systemic treatment options are available depending on the severity of nail psoriasis. Treatment can prevent pain, stress, and a worsening quality of life.²⁴

Psoriatic nail disease is associated with pain, severe joint¹⁹ and skin involvement,²⁵ psychological stress,^{10,26} poor quality of life, and higher disease activity in patients with psoriasis²⁵ and with PsA.²⁷ The harmful and negative effects of nail involvement may be more serious in PsA patients than in psoriatic patients.²⁸ Nail psoriasis is frequently scored using designated tools, including the nail psoriasis severity index (NAPSI) or nail visual analog scale (VAS). The present study focused on the particular features of psoriatic nail change, including ridging²⁹ (not included in the NAPSI), pitting, onycholysis, splinter hemorrhages, subungual hyperkeratosis, and oil-drop discoloration instead of the NAPSI. Although studies have raised awareness of nail disease as a pioneer sign and an indicator of the occurrence of PsA,²⁶ these are relatively scarce. Accordingly, we assessed clinical characteristics, nail psoriasis prevalence, and the impact of nail psoriasis on disease activity in PsA patients.

2 | MATERIALS AND METHODS

This cross-sectional multicenter study was conducted by the Turkish League Against Rheumatism PsA Network using patients recruited from 25 hospitals in Turkey. Individuals who met the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria³⁰ were enrolled after informed consent was obtained. The study adhered to the Helsinki Declaration, and its protocol was approved by the local ethics committee of Sakarya University. Patients under 18 years of age or presenting with malignancy or with other rheumatic conditions, such as systemic sclerosis, rheumatoid arthritis, or systemic lupus erythematosus, were not accepted. Patients were divided into two groups for those who had nail psoriasis and those without nail psoriasis.

The following demographic and clinical variables of all patients were evaluated: age, sex, body mass index, age at onset of disease, disease duration, and severity and type of skin psoriasis. Using various methods, the characteristics of the following disease-related symptoms were calculated: pain (VAS-P), fatigue (VAS-F), patient global assessment (VAS-PtG), physician global assessment (VAS-PG), swollen joint counts (SJC) (0-66), and tender joint counts (TJC) (0-68). Other tools used in this study were the Functional Assessment of Chronic Illness Therapy (FACIT),³¹ Short-Form 36 (SF-36),³² Fibromyalgia Rapid Screening Tool (FIRST),³³ PsA Quality of Life Questionnaire (PsAQoL),³⁴ Hospital Anxiety and Depression Scale (HADS),³⁵ Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),³⁶ the

Bath Ankylosing Spondylitis Functional Index (BASFI),³⁷ and the Psoriasis Area Severity Index (PASI).³⁸

The patients' fingernails and toenails were evaluated and existing nail changes were recorded, including pitting, onycholysis, longitudinal ridging, splinter hemorrhages, subungual hyperkeratosis, and oil-drop discoloration.¹⁰ Nail psoriasis features were detected as one or more types of changes on the fingernails and toenails.

SPSS version 22 (IBM, Armonk, NY, USA) software was used for statistical analysis. Distribution of the data for normality was analyzed using the Kolmogorov-Smirnov test. The difference between groups was determined by Student *t* test or the Mann-Whitney *U* test. The χ^2 test or the Fisher exact test was used for analysis of categorical data, if suitable. The results of parametric variables are stated as mean ($\pm$ standard deviation); the results of nonparametric variables are stated as median and interquartile range. Percentages and frequencies are used for categorical variables.

3 | RESULTS

For this study, 1122 patients with PsA (65% of them female) were recruited. Comparisons between demographic and clinical characteristics of patients with nail psoriasis and those without are presented in Table 1. Of the 1122 patients, 645 (57.5%) had nail psoriasis. Female patients dominated both groups; 64% of the group with nail psoriasis and 67% of the group without (410 vs 318; $P = 0.282$). In patients with nail psoriasis, the median age and body mass index were statistically higher than in patients without (48 vs 46 years and 29 vs 28 kg/m² respectively: both $P < 0.05$). In terms of median age of disease onset, age of diagnosis, first symptom duration, diagnosis duration, mean inflammatory back pain, spondylitis, peripheral arthritis, enthesopathy, and dactylitis, the two groups were similar (all $P > 0.05$) (Table 1).

Although the monoarthritis, polyarthritis, and oligoarthritis subtypes of PsA were higher in the nail involvement group than in the group without ($P < 0.05$), there was no statistically significant difference between the two groups in terms of DIP joint arthritis and arthritis mutilans ($P > 0.05$). The proportion of patients receiving corticosteroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARD) was higher in patients with nail psoriasis (all $P < 0.05$). There was no difference in the two groups of patients between biological and targeted synthetic DMARD and combination DMARD therapies (all $P > 0.05$). Patients with nail psoriasis had a higher median score on PtGA, PGA, VAS-P, VAS-F, FACIT, TJC, SJC, CRP level, and DAS28-CRP than patients without nail psoriasis (all $P < 0.05$). Median BASDAI, BASFI, and ESR scores were similar between both groups ($P > 0.05$). The median PsAQoL and HADS-anxiety scores were higher, and median SF-36 Mental component and SF-36 Physical component scores were lower in patients with nail psoriasis than without (all $P < 0.001$). The HADS-depression scores were similar in both groups.

TABLE 1 Comparison of demographic and clinical characteristics, and of subtype of joint disease in groups of patients with PsA with nail psoriasis vs those without nail psoriasis

	With nail psoriasis		Without nail psoriasis		P
	57.5% (n = 645)		42.5% (n = 477)		
	Valid n		Valid n		
Gender, female, n (%)	645	410 (64)	477	318 (67)	0.282
Age (years), median (IQR)	645	48 (39-56)	477	46 (37-54)	0.001
BMI (kg/m ²), median (IQR)	645	29 (25-32)	477	28 (25-31)	0.02
Age of disease onset (years), median (IQR)	520	30 (20-42)	379	29 (19-39)	0.194
Age of diagnosis (years), median (IQR)	520	31 (20-42)	379	30 (20-40)	0.261
Symptom duration (years), median (IQR)	645	7 (3-14)	477	6 (3-13)	0.065
Diagnosis duration (years), median (IQR)	645	5 (2-10)	477	4 (1-10)	0.205
Inflammatory back pain, n (%)	645	290 (45)	477	230 (48)	0.279
Spondylitis, n (%)	645	258 (40)	477	167 (35)	0.089
Peripheral arthritis, n (%)	645	426 (66)	477	290 (61)	0.07
Enthesopathy, n (%)	645	274 (42)	477	185 (39)	0.213
Dactylitis, n (%)	645	223 (35)	477	101 (21)	0.224
Subtypes of PsA, n (%)					
Monoarthritis	645	60 (9)	477	55 (12)	<0.001
Oligoarthritis	645	175 (27)	477	102 (21)	0.027
Polyarthritis	645	179 (28)	477	93 (19)	0.001
DIP joint arthritis	645	30 (5)	477	13 (3)	0.097
Arthritis mutilans	645	3 (0.5)	477	1 (0.2)	0.478
Current medication, n (%)					
csDMARD	645	365 (57)	477	239 (50)	0.007
b/tsDMARD	645	171 (27)	477	144 (30)	0.121
Combination DMARD	645	62 (10)	477	42 (9)	0.495
Corticosteroids	645	69 (11)	477	36 (8)	0.027
PtGA, median (IQR)	645	5 (3-6)	477	4 (2-6)	0.002
PGA, median (IQR)	645	4 (2-5)	477	3 (2-5)	<0.001
VAS-P, median (IQR)	645	5 (3-7)	477	5 (2-6)	0.005
VAS-F, median (IQR)	645	5 (4-8)	477	5 (2-7)	<0.001
FACIT score, median (IQR)	645	20 (12-27)	477	17 (10-25)	<0.001
ESR (mm/hour), median (IQR)	645	17 (10-28)	477	15 (9-26)	0.168
CRP (mg/L), median (IQR)	645	3 (1-7)	477	3 (1-5)	0.01
BASDAI score (0-10), median (IQR)	560	4 (3-6)	375	4 (3-6)	0.178
BASFI score (0-10), median (IQR)	433	3 (2-5)	282	3 (2-5)	0.051
Tender joint count, median (IQR)	497	5 (2-10)	296	3 (2-8)	<0.001
Swollen joint count, median (IQR)	290	2 (1-4)	167	2 (1-3)	0.011
DAS28-CRP score, median (IQR)	613	3 (3-4)	432	3 (2-4)	<0.001
PsAQoL score, median (IQR)	645	6 (1-12)	477	4 (1-10)	0.001
HADS-anxiety score, median (IQR)	645	7 (4-10)	477	6 (3-9)	<0.001
HADS-depression score, median (IQR)	645	7 (4-9)	477	6 (3-9)	0.104
SF-36 PC score, median (IQR)	645	54 (35-76)	477	63 (41-79)	<0.001
SF-36 MC score, median (IQR)	645	54 (36-74)	477	65 (39-76)	<0.001
FIRST score, median (IQR)	645	2 (0-5)	476	2 (0-4)	0.006
PASI head score, median (IQR)	645	0 (0-0)	477	0 (0-0)	<0.001



TABLE 1 (Continued)

	With nail psoriasis		Without nail psoriasis		P
	57.5% (n = 645)		42.5% (n = 477)		
	Valid n		Valid n		
PASI trunk score, median (IQR)	645	0 (0-1)	477	0 (0-0)	<0.001
PASI upper extremities score, median (IQR)	645	1 (0-1)	477	0 (0-1)	<0.001
PASI lower extremities score, median (IQR)	645	1 (0-2)	477	0 (0-1)	<0.001
PASI total score, median (IQR)	645	2 (1-4)	477	1 (0-2)	<0.001

Note: Data are shown as median percentage with interquartile range (IQR).

Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; b/ts, biological and targeted synthetic; BMI, body mass index; CRP, C-reactive protein; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; FACIT, Functional Assessment of Chronic Illness Therapy; FIRST, Fibromyalgia Rapid Screening Tool; HADS, Hospital Anxiety and Depression Scale; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PsA, psoriatic arthritis; PsAQoL, Psoriatic Arthritis Quality of Life; PtGA, patient global assessment; SF-36 MC, Short Form 36 Mental Component; SF-36 PC, Short Form-36 Physical Component; VAS, visual analogue scale. Bold value indicates Statistically significant *P* values.

Although total PASI scores were lower in all groups, patients with nail psoriasis scored higher ($P < 0.001$), demonstrating the severity of skin disease activity. PASI body part (head, upper extremities, trunk, and lower extremities) scores were higher in the nail psoriasis group than in the other group (all $P < 0.001$).

Psoriatic nail changes were present in 57.5% of the study population. As illustrated in Table 2, the most common morphological nail psoriasis feature observed on the fingernails was ridging (467; 38%), followed by pitting (252; 21%), onycholysis (120; 10%), subungual hyperkeratosis (91; 8%), oil-drop discoloration (41; 3%), and splinter hemorrhages (11; 1%). Psoriatic nail changes observed on the toenails were ridging (349; 29%), subungual hyperkeratosis (164; 14%), onycholysis (144; 12%), pitting (86; 7%), and oil-drop discoloration (26; 2%).

Features of skin disease presented as psoriasis vulgaris (905; 81%), scalp psoriasis (124; 11%), palmo-plantar psoriasis (49; 4%), erythrodermic psoriasis (33; 3%), generalized psoriasis (29; 3%), pustular psoriasis (30; 3%), and guttate psoriasis (30; 2%). Skin diseases were present concurrently in 825 (74%) patients, a history of skin disease was indicated in 269 (24%) patients, and 28 (2%) patients had no signs or history of skin disease.

4 | DISCUSSION

Our study revealed that 57.5% of patients with PsA experience psoriatic nail change, and the proportion of women was higher in both groups: those with nail psoriasis and those without nail psoriasis. Patients with nail psoriasis were slightly older, had a higher body mass index, and their increased disease activity was indicated by their elevated pain, fatigue, anxiety, and CRP levels, and higher SJC, TJC, PASI, DAS28, FACIT, and FIRST scores. PsA patients with nail involvement reported a more impaired quality of life as demonstrated by the PsAQoL and diminished physical and mental status as measured by the SF-36 Mental component and SF-36 Physical component scores than patients without nail psoriasis (all $P < 0.001$).

Subtypes of PsA, including monoarthritis, oligoarthritis, and polyarthritis, were more common in patients with nail psoriasis. Ridging was a common feature of nail involvement in both fingernails and toenails. Pitting, onycholysis, and subungual hyperkeratosis were observed frequently in the fingernails of patients with nail psoriasis.

Nail psoriasis is frequently accompanied by psoriatic arthritis, as exemplified by various studies that explored the association between nail change and small joint or DIP joint arthritis.^{20,39,40} The literature indicated up to 80% prevalence in psoriatic arthritis patients and up to 50% in psoriasis patients.¹³ Various studies examined nail psoriasis as a risk factor for the development of PsA; however, those that explored the potential influence of nail psoriasis on disease activity and clinical parameters in PSA patients were scarce. To our knowledge, the current study is one of few studies—including five that comprehensively evaluated the impact of nail psoriasis on clinical characteristics^{15,20,26,27,41} and six that reported outcomes^{19,39,40,42–44}—in PSA patients using data from a Turkish League Against Rheumatism cross-sectional study.

A recent study published by Mease et al²⁷ compared work productivity and disease activity measures in PSA patients with and without nail psoriasis and indicated that nail psoriasis, found in 40.5% of PsA patients, was associated with increased disease activity measures as demonstrated by the SJC, TJC, Disease Activity in Psoriatic Arthritis, and Psoriatic Arthritis Disease Activity Score. Our study results have expanded on this finding, demonstrating that patients with nail psoriasis had high disease activity, poorer quality of life, and impaired mental and physical states. Mease et al²⁷ measured nail involvement using the nail VAS, whereas the present study assessed by particular types of nail psoriasis features. Although nail psoriasis prevalence was lower than found in our study, this can be attributed to the higher proportion of their patients who underwent biological drug therapy (31%), whereas in our study, more patients with nail psoriasis received csDMARD and steroid therapies. In terms of receiving biological therapy in the current study, both groups of patients, with and without nail psoriasis, were similar.

TABLE 2 Detailed information of skin and nail findings of patients with PsA

	n = 1122	%
Type of psoriasis		
Psoriasis vulgaris	905	81
Erythrodermic psoriasis	33	3
Pustular psoriasis	30	3
Generalized psoriasis	29	3
Palmoplantar psoriasis	49	4
Scalp psoriasis	124	11
Guttate psoriasis	30	2
Skin findings		
Currently present	825	74
History	269	24
Never	28	2
Frequency of fingernail changes		
None	530	44
Ridging	467	38
Onycholysis	120	10
Pitting	252	21
Splinter hemorrhages	11	1
Subungual hyperkeratosis	91	8
Oil-drop discoloration	41	3
Frequency of toenail changes		
None	582	48
Pits	94	8
Ridging	349	29
Onycholysis	144	12
Pitting	86	7
Splinter hemorrhages	6	0
Subungual hyperkeratosis	164	14
Oil-drop discoloration	26	2
Location of skin disease		
Ears	216	19
Scalp	531	47
Umbilicus	212	19
Extensor areas of extremities	771	69
Gluteal cleft	82	7

Although the influence of nail psoriasis on PsA patients' quality of life is known,⁴⁵ it is often overlooked. We showed that the PsAQoL score of patients with nail involvement was higher than in patients without nail involvement ($P < 0.001$). It is one of the few studies to do so. In addition, previous studies suggested an association between onycholysis and severity of skin and joint disease.^{39,43,46} Other studies reported the connection between nail psoriasis features, including onychorrhexis, Beau lines, and nail alterations as mentioned in the NAPSI, and joint disease, especially DIP joint arthritis.^{26,40,41} Our study indicated that the two groups were similar in terms of DIP joint arthritis, whereas the PASI scores and proportion of monoarthritis, oligoarthritis, and polyarthritis were higher in patients with

nail psoriasis. These data reflect the findings of previous scholars.⁴² In addition, although joint involvement occurs 5 or 10 years after the skin disease, it may sometimes accompany the initial symptoms, and sometimes it may not occur at all.³ It has been reported that nail psoriasis leads to the development of joint disease and appears a few years before the onset of symptoms of arthritis.⁴⁷ Moreover, nail lesions are seen as early evidence of the development of arthritis.^{16,26} According to these, and because the patients did not remember exact symptom onset times, our study did not evaluate whether nail lesions developed before or after the onset of arthritis.

The clinical manifestations of nail psoriasis in our study patients were assessed using the most common characteristic nail psoriasis changes, which were also evaluated in previous studies.^{11,26} Our study upholds earlier research by showing that ridging is the most prevalent nail change in fingernails, followed by pitting, onycholysis, and subungual hyperkeratosis.^{11,40,41,46} Ridging is a common proximal nail matrix change but not a characteristic psoriatic nail change; it can be caused by other factors, such as aging, the environment, and rheumatoid arthritis.⁴¹ As such, it is not surprising that it is seen as the most frequent change.

Sandre et al⁴¹ explored the association between specific psoriatic nail changes and hand joint arthritis and revealed that pitting and onycholysis, splinter hemorrhages were common changes caused by nail psoriasis in PsA patients; our study was compatible with these results. The most common special nail change features in fingernails are pitting, onycholysis, and subungual hyperkeratosis. In our study, the most common toenail psoriatic change features were subungual hyperkeratosis (14%), onycholysis (12%), and pits (8%). The psoriatic nail features of our study are similar to those reported in previous studies.^{43,46}

Although ridging and onychorrhexis are mentioned in the literature, it is debated whether onychorrhexis, or longitudinal ridging, or nail fissures are frequently observed in the nails of patients with psoriasis of long-duration.^{11,41,48} Salomon et al¹¹ showed that pitting and longitudinal ridging of the nail matrix were commonly observed in fingernails, whereas hyperkeratosis is the most frequent nail change in fingernails and toenails of patients with psoriasis. We reported similar findings. Scarpa et al²⁰ used magnetic resonance imaging to perform nail and joint imaging and found that nail involvement was commonly associated with distal phalanx involvement, but not with DIP joint involvement. We also found no difference in DIP joint involvement between those with and without nail involvement. The majority of the literature discusses the relationship between characteristic nail lesions and joint involvement.^{18,40,43,46} In addition, scalp psoriasis, long disease duration, and the severity of the skin disease are associated with the development of PsA; but longer studies are required for evidence of PsA development.

Considering the negative effects of nail involvement and the burden of the disease for patients, early treatment is a necessity. Current treatment guidelines recommend that treatments be planned with the patient and take into consideration the presence and/or absence of all the features of PsA or its severity.^{6,21–23} If a small number (up to three) of nails are involved, topical vitamin D analogues, topical steroids, or local steroid injections can be given, either alone or as combination therapy.^{24,49} In cases with the involvement of more



than three nails, increased skin disease and arthritis, and a worsening quality of life, systemic treatments, such as csDMARD or biological treatments, are recommended.^{23,24,49} In our study, many of the patients received csDMARD therapy, namely, both patients with nail involvement (57%) and patients without nail involvement (50%). The fact that the rate of nail involvement (57.5%) in our study was higher than that (40%) in the study of Mease et al²⁷ may be a result of our more widespread use of csDMARD treatments.

The strength of this study is that in terms of nail psoriasis, it is one of the few that comprehensively evaluates PsA patient characteristics, while changes are assessed by special psoriatic nail features. There were some limitations in the study. One limitation is that the NAPS tool was not used to assess the intensity of nail alterations, nor was dermoscopy used to examine nail abnormalities. Examination with the naked eye alone may have caused some nail changes to be overlooked. If we had used the NAPS tool or dermoscopy, the validity of our study findings would undoubtedly have increased. The use of dermoscopy can be useful in recognizing early nail changes and may help in rapid diagnosis in cases of atypical clinical features of psoriatic nails.⁵⁰ However, the literature on the use of the NAPS tool by rheumatologists is controversial. The use of the NAPS tool by untrained rheumatologists may reduce its reliability.⁵¹ Not all participating physicians had been trained in the NAPS tool before the present study began, which is why we chose not to use it. Another limitation of the study is that, because of its cross-sectional nature, it was not possible to evaluate which clinical parameters improved with treatment. A limitation of our study was that considerable data were missing when we performed the statistical analyses for the TJC, SJC, BASDAI, BASFI, and DAS28. In some cases, where both axial disease and peripheral arthritis were present, it was a result of the incomplete processing of the findings in the case report form. Finally, using the DAS28-CRP as the disease activity score limited our findings, because it evaluated only 28 joints and might not have reflected the full disease activity in PsA patients.

5 | CONCLUSION

This study has shown that nail psoriasis is an often-overlooked feature of PsA, and PsA patients with nail psoriasis experience increased disease activity, lower quality of life, and diminished mental and physical status compared with those patients without nail psoriasis.

AUTHOR CONTRIBUTIONS

All authors contributed to the study conception, design, and data acquisition. Interpretation and analysis of data were performed by GC, KN, and YK. The manuscript's first draft was written by GC. KN and YK participated in drafting and revising the manuscript. All authors commented on previous versions of the manuscript and all authors approved the final version of the manuscript. KN has full access to all of the data in the study and takes responsibility for the integrity of the data. All co-authors are fully accountable for all aspects of the work.

ACKNOWLEDGEMENT

The authors thank Prof. Dr. Murat Borlu for his dermatological evaluation and contributions to the manuscript.

CONFLICT OF INTEREST

The authors report no conflict of interest or funding source.

ORCID

Gizem Cengiz <https://orcid.org/0000-0002-0021-7002>

Yaşar Keskin <https://orcid.org/0000-0003-4457-5917>

Erkan Kılıç <https://orcid.org/0000-0003-4355-4356>

Sevtap Acer Kasman <https://orcid.org/0000-0002-4805-0555>

Hakan Alkan <https://orcid.org/0000-0001-8461-9131>

Nihan Cüzdan Balta <https://orcid.org/0000-0001-7238-657X>

Cevriye Mülkoğlu <https://orcid.org/0000-0001-9113-3885>

Okan Küçükakkaş <https://orcid.org/0000-0001-6971-4229>

Ozan Volkan Yurdakul <https://orcid.org/0000-0003-4567-8133>

Meltem Alkan Melikoğlu <https://orcid.org/0000-0001-7519-9470>

Erhan Çapkin <https://orcid.org/0000-0003-2728-5934>

Öznur Kutluk <https://orcid.org/0000-0003-1037-7381>

REFERENCES

1. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. *Lancet*. 2018;391(10136):2273-2284.
2. Ocampo DV, Gladman D. Psoriatic arthritis. *F1000Res*. 2019;8:1-16.
3. Gladman D, Antoni C, Mease P, Clegg D, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis*. 2005;64(suppl 2):ii14-ii17.
4. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. *J Am Acad Dermatol*. 2009;60(2):218-224.
5. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007;370(9583):263-271.
6. Elmetts CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. *J Am Acad Dermatol*. 2019;80(4):1073-1113.
7. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. *Rheum Dis Clin North Am*. 2015;41(4):545-568.
8. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. *Am J Clin Dermatol*. 2003;4(7):441-447.
9. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/north American dermatology clinics. *J Am Acad Dermatol*. 2013;69(5):729-735.
10. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. *J Am Acad Dermatol*. 2007;57(1):1-27.
11. Salomon J, Szepletowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. *J Cutan Med Surg*. 2003;7(4):317-321.
12. Sandre MK, Rohekar S. Psoriatic arthritis and nail changes: exploring the relationship. *Semin Arthritis Rheum*. 2014;44(2):162-169.
13. Manhart R, Rich P. Nail psoriasis. *Clin Exp Rheumatol*. 2015;33(5 Suppl 93):S7-S13.
14. Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. *Psoriasis (Auckl)*. 2017;7:51-63.
15. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in



- patients with psoriasis: a population-based study. *Arthritis Rheum.* 2009;61(2):233-239.
16. Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. *Actas Dermo-Sifiliograficas.* 2015;106(6):452-457.
 17. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis—A high-resolution MRI and histological study. *Rheumatology (Oxford).* 2007;46(2):253-256.
 18. Lai TL, Pang HT, Cheuk YY, Yip ML. Psoriatic nail involvement and its relationship with distal interphalangeal joint disease. *Clin Rheumatol.* 2016;35(8):2031-2037.
 19. Antony AS, Allard A, Rambojun A. Psoriatic nail dystrophy is associated with erosive disease in the distal interphalangeal joints in psoriatic arthritis: a retrospective cohort study. *J Rheumatol.* 2019;46(9):1097-1102.
 20. Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. *J Rheumatol.* 2006;33(7):1315-1319.
 21. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. *Arthritis Rheumatol.* 2016;68(5):1060-1071.
 22. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80(4):1029-1072.
 23. Onaral D. Türkiye Psoriasis Tedavi Kılavuzu. 2021.
 24. Haderl E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail psoriasis: a review of effective therapies and recommendations for management. *Dermatol Ther (Heidelb).* 2021;11(3):799-831.
 25. Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. *Br J Dermatol.* 2010;163(3):580-585.
 26. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis—Clinically important, potentially treatable and often overlooked. *Rheumatology (Oxford).* 2004;43(6):790-794.
 27. Mease PJ, Liu M, Rebello S, et al. Association of nail psoriasis with disease activity measures and impact in psoriatic arthritis: data from the corona psoriatic arthritis/spondyloarthritis registry. *J Rheumatol.* 2021;48(4):520-526.
 28. de Jong EM, Seegers BA, Gulink MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. *Dermatology.* 1996;193(4):300-303.
 29. Ji C, Wang H, Bao C, et al. Challenge of nail psoriasis: an update review. *Clin Rev Allergy Immunol.* 2021;61(3):377-402.
 30. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum.* 2006;54(8):2665-2673.
 31. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. *J Rheumatol.* 2005;32(5):811-819.
 32. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care.* 1992;30(6):473-483.
 33. Perrot S, Bouhassira D, Fermanian J. Development and validation of the fibromyalgia rapid screening tool (FIRST). *Pain.* 2010;150(2):250-256.
 34. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. *Ann Rheum Dis.* 2004;63(2):162-169.
 35. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67(6):361-370.
 36. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. *J Rheumatol.* 1994;21(12):2286-2291.
 37. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. *J Rheumatol.* 1994;21(12):2281-2285.
 38. Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. *J Invest Dermatol.* 1996;106(1):183-186.
 39. Maejima H, Taniguchi T, Watarai A, Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. *Int J Dermatol.* 2010;49(8):901-906.
 40. Zenke Y, Ohara Y, Kobayashi D, et al. Nail findings in patients with psoriatic arthritis: a cross-sectional study with special reference to transverse grooves. *J Am Acad Dermatol.* 2017;77(5):863-867.
 41. Sandre MK, Rohekar S, Guenther L. Psoriatic nail changes are associated with clinical outcomes in psoriatic arthritis. *J Cutan Med Surg.* 2015;19(4):367-376.
 42. Soy M, Karaca N, Umit EU, Bes C, Piskin S. Joint and nail involvement in Turkish patients with psoriatic arthritis. *Rheumatol Int.* 2008;29(2):223-225.
 43. Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik psoriatic arthritis study. *Scand J Rheumatol.* 2010;39(4):299-302.
 44. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis, the unknown burden of disease. *J Eur Acad Dermatol Venereol.* 2014;28(12):1690-1695.
 45. Stewart CR, Algu L, Kamran R, et al. The impact of nail psoriasis and treatment on quality of life: a systematic review. *Skin Appendage Disord.* 2021;7(2):83-89.
 46. Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Psoriatic arthritis and onycholysis — Results from the cross-sectional Reykjavik psoriatic arthritis study. *J Rheumatol.* 2012;39(7):1441-1444.
 47. Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. *Reumatologia.* 2017;55(3):131-135.
 48. Schons KR, Knob CF, Murussi N, Beber AA, Neumaier W, Monticeli OA. Nail psoriasis: a review of the literature. *An Bras Dermatol.* 2014;89(2):312-317.
 49. Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. *J Am Acad Dermatol.* 2019;81(1):228-240.
 50. Yadav TA, Khopkar US. Dermoscopy to detect signs of subclinical nail involvement in chronic plaque psoriasis: a study of 68 patients. *Indian J Dermatol.* 2015;60(3):272-275.
 51. Lubrano E, Scrivo R, Cantini F, et al. Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists? *Arthritis Care Res.* 2012;64(3):455-458.

How to cite this article: Cengiz G, Nas K, Keskin Y, et al. The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: A cross-sectional multicenter study. *Int J Rheum Dis.* 2023;26:43-50. doi: [10.1111/1756-185X.14442](https://doi.org/10.1111/1756-185X.14442)